ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2022
The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction.
Ali A Rizvi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
29 papers cite it
this papercites it